240 related articles for article (PubMed ID: 32277576)
21. Tumour-induced osteomalacia: a literature review and a case report.
Dadoniene J; Miglinas M; Miltiniene D; Vajauskas D; Seinin D; Butenas P; Kacergius T
World J Surg Oncol; 2016 Jan; 14(1):4. PubMed ID: 26744291
[TBL] [Abstract][Full Text] [Related]
22. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia.
Habra MA; Jimenez C; Huang SC; Cote GJ; Murphy WA; Gagel RF; Hoff AO
Endocr Pract; 2008 Dec; 14(9):1108-14. PubMed ID: 19158050
[TBL] [Abstract][Full Text] [Related]
23. [FGF23 tumor induced osteomalacia with localization of neoplasm in the tympanic cavity].
Ovchinnikov AY; Khon EM; Bakotina AV; Miroshnichenko NA; Gronskaia SA; Belaya ZE
Vestn Otorinolaringol; 2023; 88(6):91-96. PubMed ID: 38153899
[TBL] [Abstract][Full Text] [Related]
24. Tumor-induced osteomalacia: experience from a South American academic center.
González G; Baudrand R; Sepúlveda MF; Vucetich N; Guarda FJ; Villanueva P; Contreras O; Villa A; Salech F; Toro L; Michea L; Florenzano P
Osteoporos Int; 2017 Jul; 28(7):2187-2193. PubMed ID: 28341900
[TBL] [Abstract][Full Text] [Related]
25. Ameloblastic Fibroodontoma of Mandible Causing Tumor Induced Osteomalacia: A Case Report with Review of 88 Phosphaturic Oral Neoplasms.
Mishra D; Kaur H; Bhalla AS; Manchanda S; Sasikumar J; Agarwal B; Roychoudhury A
Head Neck Pathol; 2021 Sep; 15(3):975-988. PubMed ID: 33394371
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant.
Shiba E; Matsuyama A; Shibuya R; Yabuki K; Harada H; Nakamoto M; Kasai T; Hisaoka M
Diagn Pathol; 2016 Mar; 11():26. PubMed ID: 26956379
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor receptor 1 (FGFR1) expression in phosphaturic mesenchymal tumors.
Tajima S; Fukayama M
Int J Clin Exp Pathol; 2015; 8(8):9422-7. PubMed ID: 26464698
[TBL] [Abstract][Full Text] [Related]
28. Challenges in the management of tumor-induced osteomalacia (TIO).
Brandi ML; Clunie GPR; Houillier P; Jan de Beur SM; Minisola S; Oheim R; Seefried L
Bone; 2021 Nov; 152():116064. PubMed ID: 34147708
[TBL] [Abstract][Full Text] [Related]
29. The genetic polymorphisms of XPR1 and SCL34A3 are associated with Fanconi syndrome in Chinese patients of tumor-induced osteomalacia.
Jiang Y; Li X; Feng J; Li M; Wang O; Xing XP; Xia WB
J Endocrinol Invest; 2021 Apr; 44(4):773-780. PubMed ID: 32725396
[TBL] [Abstract][Full Text] [Related]
30. Locally aggressive and multifocal phosphaturic mesenchymal tumors: two unusual cases of tumor-induced osteomalacia.
Higley M; Beckett B; Schmahmann S; Dacey E; Foss E
Skeletal Radiol; 2015 Dec; 44(12):1825-31. PubMed ID: 26341245
[TBL] [Abstract][Full Text] [Related]
31. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
[TBL] [Abstract][Full Text] [Related]
32. Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor-Induced Osteomalacia.
Hartley IR; Roszko KL; Li X; Pozo K; Streit J; Del Rivero J; Magone MT; Smith MR; Vold R; Dambkowski CL; Collins MT; Gafni RI
JBMR Plus; 2022 Aug; 6(8):e10661. PubMed ID: 35991529
[TBL] [Abstract][Full Text] [Related]
33. Identification of a novel loss-of-function PHEX mutation, Ala720Ser, in a sporadic case of adult-onset hypophosphatemic osteomalacia.
Goljanek-Whysall K; Tridimas A; McCormick R; Russell NJ; Sloman M; Sorani A; Fraser WD; Hannan FM
Bone; 2018 Jan; 106():30-34. PubMed ID: 28982589
[TBL] [Abstract][Full Text] [Related]
34. Tumor-induced Osteomalacia: A Comprehensive Review.
Minisola S; Fukumoto S; Xia W; Corsi A; Colangelo L; Scillitani A; Pepe J; Cipriani C; Thakker RV
Endocr Rev; 2023 Mar; 44(2):323-353. PubMed ID: 36327295
[TBL] [Abstract][Full Text] [Related]
35. Tumor-Induced Osteomalacia.
Florenzano P; Hartley IR; Jimenez M; Roszko K; Gafni RI; Collins MT
Calcif Tissue Int; 2021 Jan; 108(1):128-142. PubMed ID: 32504138
[TBL] [Abstract][Full Text] [Related]
36. Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia.
Ito N; Shimizu Y; Suzuki H; Saito T; Okamoto T; Hori M; Akahane M; Fukumoto S; Fujita T
J Intern Med; 2010 Oct; 268(4):390-4. PubMed ID: 20698924
[No Abstract] [Full Text] [Related]
37. Tumor induced osteomalacia from a peripheral mesenchymal tumour of the foot.
Strydom A; Greeff W; Ferrao PNF; Saragas NP
Foot (Edinb); 2023 May; 55():101979. PubMed ID: 36871520
[TBL] [Abstract][Full Text] [Related]
38. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
Imel EA; Peacock M; Pitukcheewanont P; Heller HJ; Ward LM; Shulman D; Kassem M; Rackoff P; Zimering M; Dalkin A; Drobny E; Colussi G; Shaker JL; Hoogendoorn EH; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2006 Jun; 91(6):2055-61. PubMed ID: 16551733
[TBL] [Abstract][Full Text] [Related]
39. Phosphaturic mesenchymal tumors: A review and update.
Folpe AL
Semin Diagn Pathol; 2019 Jul; 36(4):260-268. PubMed ID: 31301876
[TBL] [Abstract][Full Text] [Related]
40. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients.
Zuo QY; Wang H; Li W; Niu XH; Huang YH; Chen J; You YH; Liu BY; Cui AM; Deng W
BMC Musculoskelet Disord; 2017 Sep; 18(1):403. PubMed ID: 28934935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
